Answers are grounded in this paper and cite their sources.
High dose aminobisphosphonates are most effective for the treatment of acute hypercalcaemia and delay time to relapse. Bisphosphonates significantly reduce SREs and delay the time to first SRE in patients with bony metastatic disease but do not affect survival. Benefit is demonstrated after administration for at least 6-12 months. The greatest body of evidence supports the use of intravenous aminobisphosphonates. Further evidence is required to support use in the adjuvant setting.
No takes yet. Share an insight, caveat, or question.
Ross et al. (2004) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: